|
🦁
|
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
17 auth.
C. Mehlman,
J. Cadranel,
G. Rousseau-Bussac,
R. Lacave,
A. Pujals,
N. Girard,
C. Callens,
V. Gounant,
N. Theou-Anton,
S. Friard,
...
J. Trédaniel,
H. Blons,
C. Dujon,
B. Duchemann,
P. Schischmanoff,
T. Chinet,
E. Giroux Leprieur
|
6 |
2019 |
6
🦁
|
|
🐜
|
Surfaces and equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the emergency department at a university hospital
72 auth.
Olivier Peyrony,
S. Ellouze,
J. Fontaine,
Micheline Thegat-Le Cam,
M. Salmona,
L. Feghoul,
N. Mahjoub,
S. Mercier-Delarue,
A. Gabassi,
C. Delaugerre,
J. Le Goff,
Y. Achili,
L. Adès,
L. Aguinaga,
G. Archer,
...
A. Benattia,
B. Berçot,
A. Bergeron,
R. Bertinchamp,
L. Bondeelle,
J. Bouaziz,
D. Bouda,
D. Boutboul,
I. Brindel Berthon,
E. Brugnet,
S. Caillat Zucman,
S. Cassonnet,
K. Celli Lebras,
J. Chabert,
M. Chaix,
S. Chevret,
M. Clément,
C. Davoine,
N. De Castro,
E. de Kerviler,
C. de Margerie-Mellon,
F. Depret,
B. Denis,
L. Djaghout,
C. Dupin,
D. Farge-Blancel,
C. Fauvaux,
H. Fenaux,
E. Feredj,
D. Feyeux,
V. Frémeaux-Bacchi,
L. Galicier,
J. Garestier,
S. Harel,
A. L. Jegu,
E. Kozakiewicz,
A. Lebel M Baye,
P. Le Guen,
E. Lengliné,
G. Liégeon,
G. Lorillon,
I. Madelaine Chambrin,
G. Martin de Frémont,
S. Maylin,
C. Mehlman,
M. Meunier,
J. Molina,
F. Morin,
É. Oksenhendler,
R. Peffault de La Tour,
B. Plaud,
M. Rouveau,
J. Saussereau,
N. Schnepf,
J. Soret,
A. Tazi,
M. Tremorin
|
4 |
2020 |
4
🐜
|
|
🦁
|
Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer
11 auth.
C. Mehlman,
Paul Takam Kamga,
A. Costantini,
C. Julié,
C. Dumenil,
J. Dumoulin,
...
J. Ouaknine,
V. Giraud,
T. Chinet,
J. Emile,
E. Giroux Leprieur
|
4 |
2021 |
4
🦁
|
|
🦁
|
Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib.
7 auth.
C. Mehlman,
N. Chaabane,
R. Lacave,
K. Kerrou,
A. Ruppert,
J. Cadranel,
...
V. Fallet
|
3 |
2019 |
3
🦁
|
|
🐜
|
Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports
9 auth.
Lionel Michaux,
A. Perrier,
C. Mehlman,
Hussa Alshehhi,
Antonin Dubois,
R. Lacave,
...
F. Coulet,
J. Cadranel,
V. Fallet
|
2 |
2023 |
2
🐜
|
|
🦁
|
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.
17 auth.
C. Mehlman,
A. Swalduz,
Isabelle Monnet,
Clara Morin,
Marie Wislez,
F. Guisier,
H. Curcio,
P. du Rusquec,
A. Cortot,
V. Gounant,
...
B. Abbar,
B. Duchemann,
E. Giroux-Leprieur,
Thomas Pierret,
F. Quilot,
J. Cadranel,
V. Fallet
|
0 |
2024 |
0
🦁
|
|
🦁
|
995P Effectiveness of combination of osimertinib with another targeted therapy in advanced EGFR mutated non-small cell lung cancer harbouring other oncogenic drivers: The real-world COMPOSIT study
16 auth.
C. Mehlman,
A. Swalduz,
I. Monnet,
C. Morin,
F. Guisier,
H. Curcio,
P. du Rusquec,
A. Cortot,
V. Gounant,
B. Abbar,
...
B. Duchemann,
E. Giroux-Leprieur,
T. Pierret,
F. Quilot,
J. Cadranel,
V. Fallet
|
0 |
2022 |
0
🦁
|
